In contrast, another report showed that HER2+ breast cancer cell lines with de novo resistance to trastuzumab were not sensitized by β1 integrin inhibition, presumably because they maintain HER2 hyperphosphorylation. The gene discussed is ERBB2; the disease is breast cancer.